Ignite Creation Date:
2024-05-06 @ 3:32 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04669496
Status:
RECRUITING
Last Update Posted:
2021-07-07
First Post:
2020-12-14
Brief Title:
Phase II-III Clinical Trial of PD1 Antibody Toripalimab Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Gemox Chemotherapy |
| Intrahepatic Cholangiocarcinoma |
| PD1 Antibody |
| Lenvatinib |
Keywords: